Inogen (Nasdaq: INGN) has launched the Rove 4 portable oxygen concentrator (POC) to the American market.
In an October news announcement, Inogen, headquartered in Goleta, California, said the Rove 4 POC has “an additional, fourth flow setting delivering up to 840ml/min of medical-grade oxygen, in a lightweight user-friendly design of less than 3 lbs. and three battery configurations providing up to five hours and 45 minutes of operation.”
“We are pleased to announce the launch of Rove 4, a meaningful step forward in our intent to serve patients in need of oxygen therapy while allowing them to remain ambulatory,” said Kevin Smith, Inogen’s president/CEO. “This is an important milestone, and we are excited to work with patients and prescribers to deliver the positive impact of Rove 4 technology.”
The new POC “utilizes Inogen’s patented pulse-dose Intelligent Delivery Technology,” which was designed to provide “unparalleled triggering sensitivity to quickly detect a breath and deliver oxygen within the first 250 milliseconds of the inspiration, where oxygen has the most effect of lung gas exchange.”
Inogen noted that the Rove 4 was “designed for reliability” and has an expected service life of up to eight years.
“It is exciting to see the continuing innovation of portable oxygen concentrators to help advance the ambulation of long-term oxygen therapy patients,” said Neil MacIntyre, M.D., Duke University Medical Center in the launch announcement. “The Inogen Rove 4 should play a meaningful role on this journey.”
